2026-04-14T03:55:18Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/125912025-10-04T05:20:18Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Bernardez, Beatriz author Bruna, Jordi author Arriola, Edurne author De Castro, Javier author Garcia Campelo, Rosario author Bernabé, Reyes author FELIP, ENRIQUETA author 2025-02-12T13:37:02Z 2025-02-12T13:37:02Z 2024-08 Consenso; Eventos adversos; Cáncer de pulmón de células no pequeñas Consens; Esdeveniments adversos; Càncer de pulmó de cèl·lules no petites Consensus; Adverse events; Non-small cell lung cancer The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. However, lorlatinib is not exempt from potential adverse events. Adequate monitoring and management of these adverse events are critical for increasing patient adherence to lorlatinib, thereby maximizing the benefits of treatment and minimizing the risks associated with treatment discontinuation. Considering that the adverse events of lorlatinib can affect different organs and systems, the participation of a multidisciplinary team, including cardiologists, neurologists, internal medicine specialists, and oncology pharmacists, is needed. This article presents specific and pragmatic strategies for identifying and treating the most relevant adverse events associated with lorlatinib in patients with advanced ALK-positive NSCLC based on the clinical experience of a multidisciplinary panel of experts. This project was developed with funding from Pfizer. Decisió de grup Proteïnes quinases - Inhibidors - Ús terapèutic - Efectes secundaris Pulmons - Càncer - Tractament DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors Other subheadings::Other subheadings::/therapeutic use CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptor Protein-Tyrosine Kinases::Anaplastic Lymphoma Kinase Other subheadings::Other subheadings::Other subheadings::/antagonists & inhibitors ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas Otros calificadores::Otros calificadores::/uso terapéutico COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores proteína-tirosina cinasas::cinasa del linfoma anaplásico Otros calificadores::Otros calificadores::Otros calificadores::/antagonistas & inhibidores Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer